PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022
GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.
GlobalData predicts that relative patient share for the three MenC conjugate vaccines will remain unchanged for the duration of the forecast period because Nuron Biotech’s Meningitec, Novartis’ Menjugate kit, and Baxter’s NeisVac-C possess nearly identical clinical profiles and price points. The MenC conjugate patient share is largely determined by prescriber preference in Spain and therefore is not expected to change drastically during the forecast period. In addition, GlobalData believes that an expected change in the booster administration age, from two to 11 years of age, will not dramatically alter sales, although a small coverage rate decrease associated with the older age group may occur (MSSSI, 2013).
Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Spain from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting Spain Meningococcal Vaccines market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2012-2022 in Spain
Sales for Meningococcal Vaccines in Spain
The Spain meningococcal vaccine market wasworth approximately $67.8 million in 2012, with aprojected negative compound annual growth rate(CAGR) of 0.4%, to reach a total of $65.0 million in2022. These sales are driven primarily by theadministration of MenC conjugate vaccines toinfants and toddlers as part of the country’srecommended immunization schedule.
GlobalData expects that some of the mostimportant drivers of Spain market growth over thenext decade will be:
The entrance of serogroup B vaccines, particularlyNovartis’ Bexsero, into the marketplace has thepotential to drive growth in Spain’s meningococcalvaccines market.
GlobalData believes that notable barriers to growthof Spain meningococcal vaccines market willinclude:
A cost-conscious government will oppose theexpansion of vaccine coverage beyond thosealready recommended for routine vaccination,capping market growth to within these narrowage segments. The declining incidence rates ofmeningococcal disease contribute to thisposition.
The low pricing of polysaccharide vaccines inSpain prevents their complete elimination andfunnels some sales away from the moreexpensive conjugate vaccines.